Membership offers new access to potential funding and opportunities to meaningfully influence how ARPA-H addresses key challenge areas
MASON, Ohio – May 1, 2024 – Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that their application for spoke membership in ARPA-H’s Investor Catalyst Hub has been accepted. Intended to catalyze innovative solutions and help make them broadly available to all Americans, the Investor Catalyst Hub is one of the three key regional hubs that form the foundation for ARPANET-H, ARPA-H’s national health innovation network.
Genetesis’s acceptance into the Investor Catalyst Hub comes at a time of increased focus on women’s health research and outcomes. Most recently, First Lady Dr. Jill Biden announced the ARPA-H Sprint for Women’s Health, a commitment of $100 million in funding for transformative research and solutions supporting key women’s health initiatives.
Genetesis itself has committed to contributing to the elimination of disparities in cardiovascular outcomes between men and women since initiating research into coronary microvascular dysfunction (CMD). Today, CMD is understood to disproportionately impact women over men, so much so that some even refer to CMD as a presentation of “female-pattern cardiovascular disease”. Worse still, contemporary studies have revealed a markedly worse prognosis for afflicted patients, with some studies noting a 5-fold overall increase in all-cause mortality.
“Beyond the statistics lies a constant struggle endured by countless women grappling with misunderstood symptoms that disrupt their lives and wellbeing,” said Rhea Malhotra, Vice President of Product at Genetesis. “I’m hopeful that initiatives like these can quickly snowball into much better outcomes for women suffering from ischemic heart diseases like CMD.”
ARPA-H, or the Advanced Research Projects Agency for Health, is a relatively new agency within the National Institutes of Health (NIH) and is modeled after the Defense Advanced Research Projects Agency (DARPA), which is credited by many with developing the initial communications technologies necessary for the eventual development of the internet.
For more information about the ARPA-H Investor Catalyst Hub, visit https://investorcatalysthub.org/.
About Genetesis
To support the ischemia-first paradigm physicians need to adequately address the entire spectrum of ischemic heart disease, Genetesis, Inc. has translated over 60 years of magnetocardiography research into CardioFlux MCG, a 90-second cardiac imaging modality administered to patients without the need for ionizing radiation, pharmaceuticals, or induced stress. CardioFlux MCG has already been 510(k) cleared by the FDA and is currently being studied for its potential to provide patients and physicians with a near-instant functional assessment of myocardial ischemia, including the ability to independently assess microvascular function.
Based in Mason, Ohio, Genetesis has been working to redefine the way ischemic heart disease is detected and understood since 2013. For more information, visit https://www.genetesis.com.
Contact
Ryan Yoo
Chief of Staff
ryan.yoo@genetesis.com
(949) 742-0562